Thursday, March 21, 2013
Researchers at The University of British Columbia have
used a mechanism-based approach to design irreversible inhibitors of influenza
virus neuraminidase that could have activity against flu
strains resistant to marketed inhibitors of the target.1 The new molecules
are being developed by CDRD Ventures Inc., the
venture arm of The Centre for Drug Research and Development, a
public-private partnership that commercializes discoveries from Canadian
Osherovich, L. SciBX 6(11); doi:10.1038/scibx.2013.254 Published online
March 21, 2013
1. Kim, J.-H. et al.
Science; published online Feb. 21, 2013; doi:10.1126/science.1232552 Contact:
Stephen G. Withers, The University of British Columbia, Vancouver, British
Columbia, Canada e-mail: firstname.lastname@example.org
AND INSTITUTIONS MENTIONED
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX), Durham, N.C.
Biota Pharmaceuticals Inc. (NASDAQ:BOTA), Rockville, Md.
The Centre for Drug Research and Development, Vancouver, British Columbia, Canada
CDRD Ventures Inc., Vancouver, British Columbia, Canada
Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan
Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Green Cross Corp., Yongin-Si, South Korea
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
Shionogi & Co. Ltd. (Tokyo:4507; Osaka:4507), Osaka, Japan
The University of British Columbia, Vancouver, British Columbia, Canada
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Cambridge, Mass.